Erratum: Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAFV600E colorectal cancer (Clinical Cancer Research (2013) 19 (2688-98))
Publication
, Journal Article
Coffee, EM; Faber, AC; Roper, J; Sinnamon, MJ; Goel, G; Keung, L
Published in: Clinical Cancer Research
July 15, 2013
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Clinical Cancer Research
DOI
EISSN
1557-3265
ISSN
1078-0432
Publication Date
July 15, 2013
Volume
19
Issue
14
Start / End Page
4018
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Coffee, E. M., Faber, A. C., Roper, J., Sinnamon, M. J., Goel, G., & Keung, L. (2013). Erratum: Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAFV600E colorectal cancer (Clinical Cancer Research (2013) 19 (2688-98)). Clinical Cancer Research, 19(14), 4018. https://doi.org/10.1158/1078-0432.CCR-13-1433
Coffee, E. M., A. C. Faber, J. Roper, M. J. Sinnamon, G. Goel, and L. Keung. “Erratum: Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAFV600E colorectal cancer (Clinical Cancer Research (2013) 19 (2688-98)).” Clinical Cancer Research 19, no. 14 (July 15, 2013): 4018. https://doi.org/10.1158/1078-0432.CCR-13-1433.
Coffee EM, Faber AC, Roper J, Sinnamon MJ, Goel G, Keung L. Erratum: Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAFV600E colorectal cancer (Clinical Cancer Research (2013) 19 (2688-98)). Clinical Cancer Research. 2013 Jul 15;19(14):4018.
Coffee, E. M., et al. “Erratum: Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAFV600E colorectal cancer (Clinical Cancer Research (2013) 19 (2688-98)).” Clinical Cancer Research, vol. 19, no. 14, July 2013, p. 4018. Scopus, doi:10.1158/1078-0432.CCR-13-1433.
Coffee EM, Faber AC, Roper J, Sinnamon MJ, Goel G, Keung L. Erratum: Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAFV600E colorectal cancer (Clinical Cancer Research (2013) 19 (2688-98)). Clinical Cancer Research. 2013 Jul 15;19(14):4018.
Published In
Clinical Cancer Research
DOI
EISSN
1557-3265
ISSN
1078-0432
Publication Date
July 15, 2013
Volume
19
Issue
14
Start / End Page
4018
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis